| Symbol
| XPO1
| contributors: mct/pgu - updated : 04-02-2019
|
| HGNC name
| exportin 1 (CRM1 homolog, yeast)
|
| HGNC id
| 12825
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| constitutional
|
| translocation
|
| protein chimeric
| | -
| | tumoral
|
|
| --over
|
|
in cervical cancer and critical for cancer cell survival and proliferation  | | tumoral
|
|
| --over
|
| |
overexpressed in cancer | | tumoral
| somatic mutation
|
|
|
| |
in primary mediastinal diffuse large B cell lymphoma and classical Hodgkin lymphoma | | tumoral
|
|
| --over
|
| |
in oesophageal cancer and is required for the proliferation and survival of oesophageal cancer cells | |
| Susceptibility
|
to autism spectrum disorders (ASD) |
| Variant & Polymorphism
SNP
| rs6735330 was associated with were associated with ASD |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| cancer | | | |
| promising candidate as both biomarker and potential anticancer therapeutic target | | cancer | reproductive | prostate | |
| XPO1 inhibition could be a novel promising agent used in combination with conventional chemotherapeutics and AR-targeted therapy for the better treatment of PCa, especially castrate-resistant prostate cancer (CRPC) | | cancer | | | |
| therapeutic targeting of XPO1 has emerged as a novel cancer treatment strategy |
| | | |